A new 13G filing with the Securities and Exchange Commission revealed that James E. Flynn‘s Deerfield Management has acquired 1.23 million common shares of Blueprint Medicines Corp (NASDAQ:BPMC), which represent 4.51% of the company’s stock. The acquisition represents a new addition to Deerfield Management’s portfolio.
Blueprint Medicines Corp (NASDAQ:BPMC) is a biopharmaceutical company that works to discover therapies to help people who suffer from genomically defined diseases induced by abnormal kinase activation. Over the past 12 months, the company’s shares have gained 65.51%. For the second quarter of 2016, the company reported collaboration revenue of $7.07 million, and a loss per share of $0.70, compared to revenue of $2.69 million and a loss per share of $0.81 for the corresponding quarter in 2015.
Out of the 749 hedge funds followed by Insider Monkey which filed 13Fs for the June quarter, 12 were bullish on Blueprint Medicines Corp (NASDAQ:BPMC) at the end of June, up by one from the end of March. Some of the largest positions in the company on June 30 were held by Richard Driehaus’ Driehaus Capital (760,303 shares), Eli Casdin’s Casdin Capital (340,000 shares), and James A. Silverman’s Opaleye Management (250,000 shares).
You can access the original SEC filing by clicking here.
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|Deerfield Management Company||0||1,231,343||0||1,231,343||1,231,343||4.51%|
|Deerfield International Master Fund||0||692,015||0||692,015||692,015||2.54%|
Page 1 of 12 – SEC Filing
(Name of Issuer)